{"id":192963,"date":"2026-08-10T11:56:03","date_gmt":"2026-08-10T06:26:03","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=192963"},"modified":"2026-08-10T11:56:04","modified_gmt":"2026-08-10T06:26:04","slug":"ishita-drugs-q1-results-fy27-pat-0-23-crore","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/ishita-drugs-q1-results-fy27-pat-0-23-crore\/","title":{"rendered":"Ishita Drugs Q1 FY27 Results: Revenue Rs 3 Cr, PAT Rs 0.23 Cr and Key Highlights"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Ishita Drugs Q1 FY27 results declared August 8, 2026. Revenue Rs 3 Cr (-41.76% YoY). PAT Rs 0.23 Cr (-23.85% YoY). CMP Rs 74.37 (+1.3%).<\/em><\/p>\n<p>Ishita Drugs Q1 FY27 results were announced on August 8, 2026, standalone. Revenue declined -41.76% YoY to Rs 3 Cr from Rs 5.00 Cr in Q1 FY26. The broader <a href=\"https:\/\/univest.in\/indices\/nifty-pharma\/nifty-pharma-share-price-today\">Nifty Pharma<\/a> index reflected mixed sentiment during the quarter.<\/p>\n<p>Operating profit stood at Rs 0.27 Cr (-15.93% YoY). PAT came in at Rs 0.23 Cr (-23.85% YoY), offering a comprehensive view of how Ishita Drugs is navigating the current pharmaceuticals environment.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=ishita-drugs-q1-fy27\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/ishita-drugs-q1-results-fy27-pat-0-23-crore\/#Ishita_Drugs_Q1_FY27_Financial_Highlights\" title=\"Ishita Drugs Q1 FY27 Financial Highlights\">Ishita Drugs Q1 FY27 Financial Highlights<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/ishita-drugs-q1-results-fy27-pat-0-23-crore\/#Ishita_Drugs_Q1_FY27_Performance_Analysis\" title=\"Ishita Drugs Q1 FY27 Performance Analysis\">Ishita Drugs Q1 FY27 Performance Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/ishita-drugs-q1-results-fy27-pat-0-23-crore\/#Key_Business_Factors_in_Ishita_Drugs_Q1_FY27_Results\" title=\"Key Business Factors in Ishita Drugs Q1 FY27 Results\">Key Business Factors in Ishita Drugs Q1 FY27 Results<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/ishita-drugs-q1-results-fy27-pat-0-23-crore\/#Revenue_Normalisation_After_Prior_Period_Headwinds\" title=\"Revenue Normalisation After Prior Period Headwinds\">Revenue Normalisation After Prior Period Headwinds<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/ishita-drugs-q1-results-fy27-pat-0-23-crore\/#Margin_Pressure_from_Cost_Headwinds\" title=\"Margin Pressure from Cost Headwinds\">Margin Pressure from Cost Headwinds<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/ishita-drugs-q1-results-fy27-pat-0-23-crore\/#PAT_Performance_and_Profitability_Trend\" title=\"PAT Performance and Profitability Trend\">PAT Performance and Profitability Trend<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/ishita-drugs-q1-results-fy27-pat-0-23-crore\/#Dividend_Details\" title=\"Dividend Details\">Dividend Details<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/ishita-drugs-q1-results-fy27-pat-0-23-crore\/#FY27_Outlook_for_Ishita_Drugs\" title=\"FY27 Outlook for Ishita Drugs\">FY27 Outlook for Ishita Drugs<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/ishita-drugs-q1-results-fy27-pat-0-23-crore\/#Ishita_Drugs_Stock_Performance_After_Q1_FY27_Results\" title=\"Ishita Drugs Stock Performance After Q1 FY27 Results\">Ishita Drugs Stock Performance After Q1 FY27 Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/ishita-drugs-q1-results-fy27-pat-0-23-crore\/#Key_Risks_for_Ishita_Drugs\" title=\"Key Risks for Ishita Drugs\">Key Risks for Ishita Drugs<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/ishita-drugs-q1-results-fy27-pat-0-23-crore\/#Sector-Specific_Risks\" title=\"Sector-Specific Risks\">Sector-Specific Risks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/ishita-drugs-q1-results-fy27-pat-0-23-crore\/#Valuation_and_Earnings_Risk\" title=\"Valuation and Earnings Risk\">Valuation and Earnings Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/ishita-drugs-q1-results-fy27-pat-0-23-crore\/#Operational_and_Financial_Risk\" title=\"Operational and Financial Risk\">Operational and Financial Risk<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/ishita-drugs-q1-results-fy27-pat-0-23-crore\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/ishita-drugs-q1-results-fy27-pat-0-23-crore\/#Frequently_Asked_Questions_on_Ishita_Drugs_Q1_FY27_Results\" title=\"Frequently Asked Questions on Ishita Drugs Q1 FY27 Results\">Frequently Asked Questions on Ishita Drugs Q1 FY27 Results<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/ishita-drugs-q1-results-fy27-pat-0-23-crore\/#When_were_Ishita_Drugs_Q1_FY27_results_declared\" title=\"When were Ishita Drugs Q1 FY27 results declared?\">When were Ishita Drugs Q1 FY27 results declared?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/ishita-drugs-q1-results-fy27-pat-0-23-crore\/#What_was_Ishita_Drugs_revenue_in_Q1_FY27\" title=\"What was Ishita Drugs revenue in Q1 FY27?\">What was Ishita Drugs revenue in Q1 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/ishita-drugs-q1-results-fy27-pat-0-23-crore\/#What_was_Ishita_Drugs_PAT_in_Q1_FY27\" title=\"What was Ishita Drugs PAT in Q1 FY27?\">What was Ishita Drugs PAT in Q1 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/ishita-drugs-q1-results-fy27-pat-0-23-crore\/#Did_Ishita_Drugs_declare_a_dividend_in_Q1_FY27\" title=\"Did Ishita Drugs declare a dividend in Q1 FY27?\">Did Ishita Drugs declare a dividend in Q1 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/ishita-drugs-q1-results-fy27-pat-0-23-crore\/#What_is_the_FY27_outlook_for_Ishita_Drugs\" title=\"What is the FY27 outlook for Ishita Drugs?\">What is the FY27 outlook for Ishita Drugs?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/ishita-drugs-q1-results-fy27-pat-0-23-crore\/#How_did_Ishita_Drugs_stock_react_to_Q1_FY27_results\" title=\"How did Ishita Drugs stock react to Q1 FY27 results?\">How did Ishita Drugs stock react to Q1 FY27 results?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Ishita_Drugs_Q1_FY27_Financial_Highlights\"><\/span><strong>Ishita Drugs Q1 FY27 Financial Highlights<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width: 100%; border-collapse: collapse; font-size: 14px;\">\n<thead>\n<tr style=\"background: #0A0E1A; color: #ffffff;\">\n<th style=\"padding: 10px; text-align: left; border: 1px solid #DDD;\">Metric<\/th>\n<th style=\"padding: 10px; text-align: center; border: 1px solid #DDD;\">Q1 FY27 (Rs Cr)<\/th>\n<th style=\"padding: 10px; text-align: center; border: 1px solid #DDD;\">Q1 FY26 (Rs Cr)<\/th>\n<th style=\"padding: 10px; text-align: center; border: 1px solid #DDD;\">YoY Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDD;\">Ishita Drugs Revenue<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD;\">3<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD;\">5.00<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD; color: red;\">-41.76%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDD;\">Operating Profit<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD;\">0.27<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD;\">0.32<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD; color: red;\">-15.93%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDD;\">Net Profit (PAT)<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD;\">0.23<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD;\">0.30<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD; color: red;\">-23.85%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDD;\">Reporting Basis<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD;\" colspan=\"3\">Standalone<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Ishita_Drugs_Q1_FY27_Performance_Analysis\"><\/span><strong>Ishita Drugs Q1 FY27 Performance Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for Live Data on This Stock<\/strong><\/a><\/p>\n<p>Ishita Drugs Q1 FY27 results reflect under-pressure fundamentals across key financial metrics. Revenue faced near-term headwinds with the top line reaching Rs 3 Cr for the April to June 2026 quarter.<\/p>\n<p>Operating profit contracted -15.93% YoY to Rs 0.27 Cr. Management is focused on cost rationalisation to restore operating leverage.<\/p>\n<p>PAT of Rs 0.23 Cr marks a -23.85% YoY movement in Ishita Drugs Q1 FY27 results. Investors monitoring Ishita Drugs Q1 FY27 results will note this as a key FY27 performance milestone.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Business_Factors_in_Ishita_Drugs_Q1_FY27_Results\"><\/span><strong>Key Business Factors in Ishita Drugs Q1 FY27 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Revenue_Normalisation_After_Prior_Period_Headwinds\"><\/span><strong>Revenue Normalisation After Prior Period Headwinds<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Ishita Drugs Q1 FY27 results reflect near-term revenue moderation of -41.76% YoY, attributed to demand normalisation, channel inventory adjustments, and competitive market dynamics in the pharmaceuticals space.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Margin_Pressure_from_Cost_Headwinds\"><\/span><strong>Margin Pressure from Cost Headwinds<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Operating profit in Ishita Drugs Q1 FY27 results stood at Rs 0.27 Cr ((-15.93% YoY)), reflecting input cost inflation, wage pressures, and competitive pricing dynamics in the pharmaceuticals business.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"PAT_Performance_and_Profitability_Trend\"><\/span><strong>PAT Performance and Profitability Trend<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Net profit (PAT) in Ishita Drugs Q1 FY27 results stood at Rs 0.23 Cr ((-23.85% YoY)). Near-term PAT moderation is being managed through cost optimisation and revenue diversification.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Dividend_Details\"><\/span><strong>Dividend Details<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>No dividend was announced alongside Ishita Drugs Q1 FY27 results. The company is likely channelling earnings toward business reinvestment and working capital needs.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"FY27_Outlook_for_Ishita_Drugs\"><\/span><strong>FY27 Outlook for Ishita Drugs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Following Ishita Drugs Q1 FY27 results, management has reiterated a recovery-focused strategy targeting operational efficiencies, cost rationalisation, and revenue diversification. The pace of recovery in the pharmaceuticals segment will be a key monitorable for investors tracking Ishita Drugs Q1 FY27 results. Consult a SEBI-registered financial advisor before making decisions.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Ishita_Drugs_Stock_Performance_After_Q1_FY27_Results\"><\/span><strong>Ishita Drugs Stock Performance After Q1 FY27 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Ishita Drugs live price and get daily stock recommendations.<\/em><\/p>\n<p>Ishita Drugs shares were trading higher at Rs 74.37 (+1.3%) on August 8, 2026, reflecting investor sentiment on the Ishita Drugs Q1 FY27 results and near-term sector outlook. The CMP of Rs 74.37 on the results date reflects broader market and sector sentiment in the pharmaceuticals space.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_for_Ishita_Drugs\"><\/span><strong>Key Risks for Ishita Drugs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Sector-Specific_Risks\"><\/span><strong>Sector-Specific Risks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>USFDA regulatory actions, pricing pressure, and API cost inflation are core risks.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Valuation_and_Earnings_Risk\"><\/span><strong>Valuation and Earnings Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Sustained earnings pressure may delay re-rating; near-term earnings visibility remains limited.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Operational_and_Financial_Risk\"><\/span><strong>Operational and Financial Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Working capital intensity and cash conversion cycle elongation could strain standalone cash flows.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Ishita Drugs Q1 FY27 results reflect under-pressure performance with revenue at Rs 3 Cr and PAT at Rs 0.23 Cr on a Standalone basis. Operating leverage and sector tailwinds will determine the FY27 growth trajectory. Investors should review management commentary and sector developments before taking positions.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Ishita_Drugs_Q1_FY27_Results\"><\/span><strong>Frequently Asked Questions on Ishita Drugs Q1 FY27 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"When_were_Ishita_Drugs_Q1_FY27_results_declared\"><\/span><strong>When were Ishita Drugs Q1 FY27 results declared?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Ishita Drugs Q1 FY27 results were declared on August 8, 2026, covering the April to June 2026 quarter on a Standalone basis.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_Ishita_Drugs_revenue_in_Q1_FY27\"><\/span><strong>What was Ishita Drugs revenue in Q1 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Ishita Drugs Q1 FY27 results show revenue of Rs 3 Cr, -41.76% compared to Rs 5.00 Cr in Q1 FY26.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_Ishita_Drugs_PAT_in_Q1_FY27\"><\/span><strong>What was Ishita Drugs PAT in Q1 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Net profit in Ishita Drugs Q1 FY27 results was Rs 0.23 Cr, -23.85% year-on-year.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Did_Ishita_Drugs_declare_a_dividend_in_Q1_FY27\"><\/span><strong>Did Ishita Drugs declare a dividend in Q1 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No dividend was announced alongside Ishita Drugs Q1 FY27 results. Check the official NSE and BSE announcements for future dividend declarations.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_FY27_outlook_for_Ishita_Drugs\"><\/span><strong>What is the FY27 outlook for Ishita Drugs?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Management has guided operational restructuring and return to profitability for FY27. Sector trends and order visibility will be key monitorables for investors.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_did_Ishita_Drugs_stock_react_to_Q1_FY27_results\"><\/span><strong>How did Ishita Drugs stock react to Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Ishita Drugs shares were trading higher at Rs 74.37 (+1.3%) on August 8, 2026 following the Ishita Drugs Q1 FY27 results. Always consult a SEBI-registered financial advisor before acting on stock price movements.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ishita Drugs Q1 FY27 results: Revenue Rs 3 Cr (-41.76% YoY), PAT Rs 0.23 Cr (-23.85% YoY). Key highlights, financial analysis and FY27 outlook.<\/p>\n","protected":false},"author":28,"featured_media":192961,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802],"class_list":["post-192963","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["192961"],"_edit_lock":["1786343167:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["74"],"rank_math_title":["Ishita Drugs Q1 FY27 Results: Revenue Rs 3 Cr | PAT Highlights"],"rank_math_description":["Ishita Drugs Q1 FY27 results: Revenue Rs 3 Cr (-41.76% YoY), PAT Rs 0.23 Cr (-23.85% YoY). Key highlights, financial analysis and FY27 outlook."],"rank_math_focus_keyword":["Ishita Drugs Q1 FY27 results"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["35293"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/08\/ishita-drugs-q1-results-fy27-pat-0-23-crore.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/192963","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=192963"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/192963\/revisions"}],"predecessor-version":[{"id":192978,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/192963\/revisions\/192978"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/192961"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=192963"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=192963"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=192963"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}